Anti hla dr ecd

Manufactured by Beckman Coulter

Sourced in United States

Anti-HLA-DR-ECD is a monoclonal antibody that targets the extracellular domain of the HLA-DR antigen. It is used in flow cytometry applications to identify and characterize cells expressing HLA-DR, which is a marker of antigen-presenting cells and activated lymphocytes.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd80 fitc, by Thermo Fisher Scientific (2 mentions) Anti cd8 pacific blue, by BioLegend (2 mentions) Anti cd69 pc5, by Beckman Coulter (2 mentions) Anti cd86 pc5, by Beckman Coulter (2 mentions) Anti cd197 apc cy7 ccr7, by BioLegend (2 mentions) Kaluza software, by Beckman Coulter (2 mentions) Anti cd80 fitc, by Beckman Coulter (2 mentions) Anti cd83 apc, by BD (2 mentions) Anti cd14 pc7, by Beckman Coulter (2 mentions) Anti cd1a pe, by Beckman Coulter (2 mentions) Anti cd4 fitc, by Beckman Coulter (2 mentions) Dxflex flow cytometer, by Beckman Coulter (1 mentions) Phosphate buffered saline (pbs), by Beckman Coulter (1 mentions) Optilyse c solution, by Beckman Coulter (1 mentions) Lp vortex mixer, by Thermo Fisher Scientific (1 mentions) Cd14 pc7, by Beckman Coulter (1 mentions) Optilyse c lysing solution, by Beckman Coulter (1 mentions) Navios flow cytometer, by Beckman Coulter (1 mentions) Anti cd86 pe, by Thermo Fisher Scientific (1 mentions) Anti cd69 pe, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

HLA-DR (15 citations) HLA-DR-ECD (9 citations) Anti-HLA-DR (5 citations)

7 protocols using anti hla dr ecd

MDSC Quantification in Hepatocellular Carcinoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

We collected 4 mL of fasting peripheral venous blood from all HCC patients before GSM–TACE, 10 days after surgery, and 30 days after surgery using heparin anticoagulation tubes. We then added 100 μL whole blood to a dry blank tube, lysed it with 500 μL OptiLyse C Lysing Solution (Beckman Coulter Diagnostics, Brea, California, US), vortexed the solution, and incubated the lysed blood at room temperature for 15 min to assure lysis was complete. Then we added 2 mL phosphate-buffered saline (PBS), and we vortexed and centrifuged the mixture at 300 g for 5 min. After centrifugation, we aspirated the supernatant, resuspended the cell pellet in 500 μL PBS, added 5 μL each of CD14, CD11b, and HLA-DR antibodies, and mixed the solution low speed for 5 s. Finally, we analyzed the samples on a flow cytometer.
2.2.2 Antibodies and laboratory equipment: To determine MDSC frequency, we performed multicolor fluorescence-activated cell sorting analysis using Beckman Coulter CytExpert software version 1.1. We also used a DxFLEX Flow Cytometer (Beckman Coulter), a Labofuge 400R Centrifuge (Thermo Fisher Scientific, Waltham, Massachusetts, US), a LP Vortex Mixer(Thermo Fisher Waltham, Massachusetts, US), and the following anti-human monoclonal antibodies: CD11b-APC-Alexa Fluor 750, CD14-PC7, anti–HLA-DR-ECD, OptiLyse C solution, and PBS (all Beckman Coulter).

Yue Y., Ren Z., Liu Y, & Zhang Y. (2019). Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma. Journal of Interventional Medicine, 2(1), 21-26.

+ Open protocol

+ Expand

Multiparameter Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used for cell surface marker evaluation: anti-CD4-PE-Cy5, anti-CD69-PE, anti-CD127-PE-Cy7, anti-CD20-PE-Cy7, anti-CD86-PE, anti-CD80-FITC (eBioscience, San Diego, CA), anti-CD25-ECD, anti-HLA-DR-ECD, and anti-CD11c-PC5 (Beckman Coulter, Brea, CA). Primary human cells or Ramos cells were suspended in FACS buffer (1× PBS, 1% BSA, 0.1% NaN₃) and incubated for 20 minutes with panels of the indicated antibodies at 4°C. After washing, cells were analyzed in a Navios flow cytometer (Beckman Coulter, Brea, CA) and data was analyzed using FlowJo 7.6 software (Tree Star, Inc., Ashland, OR). Gates used for analysis were set using appropriate isotype controls.

Rodriguez-Pinto D., Saravia N.G, & McMahon-Pratt D. (2014). CD4 T cell activation by B cells in human Leishmania (Viannia) infection. BMC Infectious Diseases, 14, 108.

+ Open protocol

+ Expand

Phenotyping H7N9 Influenza-Specific CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs from H7N9 patients were stained with A2-M1₅₈ tetramer conjugated to PE (1:200) in FACS buffer (PBS with 1% bovine serum albumin). Cells were stained with antibodies: anti-CD3-PB (BD Cat #558117, UCTH1, 1:200), anti-CD8-FITC (BD Cat #347313, SK1, 1:50), anti-CD27-PE-Cy7 (eBioscience Cat #25-0279-42, O323, 1:25), anti-CD45RA-APC-Cy7 (BD Cat #560674, HI100, 1:50), anti-HLA-DR-ECD (Beckman Coulter Cat#IM3636, Immu-357, 1:25), anti-CD38-PerCPCy5.5 (Biolegend, Cat#303522, HIT2; 1:50), anti-PD-1-APC (Biolegend #329908, EH12.2H7, 1:25), and Live/Dead-aqua 525 (Invitrogen, 1:800). Lymphocytes were washed, acquired on a FACSAria II sorter with FACS Diva software (Becton Dickinson) and analyzed with FlowJo software (Treestar).

Wang Z., Zhu L., Nguyen T.H., Wan Y., Sant S., Quiñones-Parra S.M., Crawford J.C., Eltahla A.A., Rizzetto S., Bull R.A., Qiu C., Koutsakos M., Clemens E.B., Loh L., Chen T., Liu L., Cao P., Ren Y., Kedzierski L., Kotsimbos T., McCaw J.M., La Gruta N.L., Turner S.J., Cheng A.C., Luciani F., Zhang X., Doherty P.C., Thomas P.G., Xu J, & Kedzierska K. (2018). Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease. Nature Communications, 9, 824.

+ Open protocol

+ Expand

Antigen Uptake Capacity of MDDCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

To analyze the capacity of MDDCs to capture different antigens we measured the uptake of Alexa 488-labelled dextran and DQ ovalbumin. MDDCs (10⁵) were pulsed with 5 μg of Dextran-Alexa fluor 488 (Life Technologie) or DQ-Ovalbumine (Life Technologie) during 4 h at 37°C or 4°C. Cells were washed twice, stained during 15 min at 4°C with anti-HLA-DR-ECD (Beckman Coulter) and anti-CD11c-V450 (BD Biosciences) antibodies and then fixed with 2% of paraformaldehyde. Cells were analyzed with a LSR II flow cytometer (Becton Dickinson). Cells incubated at 4°C were used as negative control.

Hamimi C., David A., Versmisse P., Weiss L., Bruel T., Zucman D., Appay V., Moris A., Ungeheuer M.N., Lascoux-Combe C., Barré-Sinoussi F., Muller-Trutwin M., Boufassa F., Lambotte O., Pancino G, & Sáez-Cirión A. (2016). Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles. PLoS ONE, 11(8), e0160251.

+ Open protocol

+ Expand

Flow Cytometry Analysis of Cell Markers

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometry was performed as previously described [26 (link),27 (link)]. Analysis of the expression levels of cell-surface markers was performed by flow cytometry. DCs were blocked for 5 min with PBS containing 10% heat inactivated human AB serum (Sigma-Aldrich, St. Louis, MO, USA), and then stained by adding the antibodies to the same buffer. All other cell types were stained on PBS containing 3% FBS. Cells were labeled with anti-CD1a-PE, anti-CD3-PC7, anti-CD4-FITC, anti-CD14-PC7, anti-CD19-ECD, anti-CD25-PC7, anti-CD69-PC5, anti-CD80-FITC, anti-CD86-PC5.5, anti-CD86-PE, anti-HLA-DR-ECD, anti-HLA-DR-PB, anti-HLA-DR-PE (all from Beckman Coulter Inc., Brea, CA, USA), anti-CD8-Pacific Blue, anti-CD71-APC-Cy7, anti-CD197-APC-Cy7 (CCR7) (all from BioLegend, San Diego, CA, USA), anti-CD83-APC (BD Biosciences, Franklin Lake, NJ, USA), and anti-CD3-PO (Abcore, Ramona, CA, USA).
Levels of surface expression on cells were estimated by flow cytometry (Gallios; Beckman Coulter, Brea, CA, USA) and analyzed using Kaluza software (Beckman Coulter, Brea, CA, USA). Entry of FITC-labeled p24 peptide into the DCs was also estimated by flow cytometry. DCs were collected 2 h, 24 h, and 48 h after complex addition, washed with PBS, and acid washed, in order to eliminate any peptide attached to the cell surface. Fluorescence was measured by flow cytometry.

Martín-Moreno A., Jiménez Blanco J.L., Mosher J., Swanson D.R., García Fernández J.M., Sharma A., Ceña V, & Muñoz-Fernández M.A. (2020). Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine. Pharmaceutics, 12(7), 656.

+ Open protocol

+ Expand

Phenotypic Analysis of Dendritic Cells and Macrophages

Check if the same lab product or an alternative is used in the 5 most similar protocols

Analysis of cell-surface phenotype of DCs and MØs was performed by flow cytometry. Cells were labeled with anti-CD4-FITC, anti-CD69-PC5, anti-CD80-FITC, anti-CD1a-PE, anti-HLA-DR-ECD, anti-CD14-PC7, anti-CD86-PC5.5 (all from Beckman Coulter Inc., Brea, CA, USA), anti-CD8-Pacific Blue, anti-CD36-APC, anti-CD197-APC-Cy7 (CCR7) (all from BioLegend, San Diego, CA, USA), anti-CCR5-PE, anti-CD209-PE, anti-CD83-APC (all from BD Biosciences, Franklin Lake, NJ, USA), anti-CXCR4-APC (RandD systems, Minneapolis, MN, USA) and anti-CD163-FITC (MBL International Corp., Woburn, WA, USA). Levels of surface expression on cells were estimated by flow cytometry (Gallios; Beckman) and analyzed using Kaluza software (Beckman).

Martín-Moreno A., Sepúlveda-Crespo D., Serramía-Lobera M.J., Perisé-Barrios A.J, & Muñoz-Fernández M.A. (2019). G2-S16 dendrimer microbicide does not interfere with the vaginal immune system. Journal of Nanobiotechnology, 17, 65.

+ Open protocol

+ Expand

Comprehensive PBMC Immunophenotyping Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral blood mononuclear cells (PBMCs) were stained in four panels containing anti-CD3-PacificBlue (PacBlue) (antibodies from BD Biosciences unless otherwise indicated), anti-CD3-Alexa700, anti-CD25-PE-Cy7, anti-CD38-PE, anti-HLA-DR-PE-Cy7, anti-CCR5-APC, anti-CD123-PerCP-Cy5.5, anti-CD16-PacBlue, anti-CD80-FITC, anti-CD83-PE, anti-CD86-APC, anti-PD1-FITC, anti-PD-L1-PE, anti-HLA class I-APC, anti-CD69-APC-Cy7; anti-CD4-Qdot655, anti-CD8-PE-Cy5.5, anti-CD14-Qdot605 (Invitrogen); anti-CD45RA-ECD, anti-CD127-PE, anti-HLA-DR-ECD, anti-CD20-ECD (Beckman Coulter); anti-CD11c-Alexa700 (eBioscience); and anti-CD27-APC-Cy7 (BioLegend). A staining reagent for dead cells (Invitrogen Aqua Live/Dead Fixable Stain) was included. Cells were then washed and fixed in PBS containing 1% paraformaldehyde or permeabilized using a FOXP3 Fix/Perm kit (BioLegend) according to the manufacturer's instructions, intracellularly stained with anti-Ki67-Alexa 488 (BD Biosciences), anti-FOXP3-PacBlue, anti-T-Bet-BV711 (BioLegend), and anti-Eomes-eFluor 660 (eBioscience), fixed, and analyzed with a LSR II cytometer (Becton Dickinson) and FlowJo.

Méndez-Lagares G., Lu D., Chen C., Terrault N., Segal M.R., Khalili M., Monto A., Shen H., Manos M.M., Lanier L.L., Ryan J.C., McCune J.M, & Hartigan-O'Connor D. (2017). Memory T-cell proliferation before HCV therapy predicts antiviral immune responses and treatment success. Journal of immunology (Baltimore, Md. : 1950), 200(3), 1124-1132.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!